Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC

Wachters, Floris M; Putten, John W. G. van; Boezen, H. Marike; Groen, Harry J.M.

doi:10.1016/j.lungcan.2004.02.006

Cited by 8 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, several studies suggest that even platinum pre-treated patients achieve high tumor responses when platinum is again used in second-line treatment. Overall responses (ORs) have ranged between 16 and 37%, and OS after initiation of second-line treatment is between 6 and 9.3 months [14][15][16][17][18][19][20][21][22][23]. However, in the majority of studies, time of progression after first-line chemotherapy, an interval that may distinguish which patients can benefit from second-line treatment, is not defined.…”

Section: Discussionmentioning

confidence: 99%

“…We summarized available data regarding secondary platinum-based chemotherapy in platinum pre-treated patients in Table 4. Previous studies have reported responses as follows: 16.7% with cisplatin (CDDP) and etoposide, or CDDP and gemcitabine [21]; 17% with pemetrexed and carboplatin [23], 18.2 [22] and 32% [19] with CDDP and docetaxel; 19.2 [18], 31 [17], and 37% [20] with carboplatin and docetaxel; 22 [16] and 30% [14] with CDDP and irinotecan, and 27% [15] with CDDP, gemcitabine, and paclitaxel. Globally, including our results, 75 of 326 patients have presented an OR of 23%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

et al. 2010

View full text Add to dashboard Cite

Because of improved therapeutic results after first-line platinum-based chemotherapy in patients with stage IV non-small-cell lung cancer (NSCLC), second-line chemotherapy may be considered for a growing number of patients. Approximately, 10% of patients have an interval time after concluding first-line platinum-based chemotherapy greater than 6 months. These patients may achieve high tumor responses when platinum is again used in second-line treatment. Twenty-three patients experiencing progression following 6 months after concluding platinum-based chemotherapy were managed with second-line treatment with carboplatin combined with gemcitabine or pemetrexed. Overall response, progression-free survival (PFS), and overall survival (OS) after initiation of second-line treatment were calculated for all patients. Median PFS after first-line treatment was 12.6 months (95% confidence interval [95% CI], 10.4-14.7 months). Partial response was achieved in 7 of 23 patients, resulting in an overall response of 30.4% (95% CI, 11.6-49.0). Following initiation of second-line chemotherapy, median PFS was 5.9 months (95% CI, 1-10.9 months) and median OS was 12.5 months (95% CI, 3.5-21.5 months). The 1-year survival rate for all patients was 61.0% (95% CI, 29.5-82.0). Adding these results to those of the 10 previously published trials, 75 of 326 patients, 23%, (95% CI, 18.7-27.3) presented an overall response with the use of second-line platinum-based chemotherapy. The use of platinum combinations as second-line chemotherapy seems to have a place in the management of patients with advanced NSCLC, especially those with an interval time to progression greater than 6 months.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Several phase II studies have shown that platinum-based chemotherapy is active in the second-line setting [18,19,20,21]. Generally, higher response rates have been reported with combinations than with platinums administered as single agents [22].…”

Section: Discussionmentioning

confidence: 99%

Non-Platinum-Based First-Line Followed by Platinum-Based Second-Line Chemotherapy or the Reverse Sequence in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis by the Lung Cancer Group of the Hellenic Oncology Research Group

et al. 2010

View full text Add to dashboard Cite

Background: Non-platinum-containing regimens have been proposed as alternatives to platinum-based doublets in the first-line treatment of patients with non-small cell lung cancer (NSCLC). However, conflicting results about their equivalence have been reported. Methods: We reviewed the records of patients enrolled in randomized controlled first-line trials conducted by the Hellenic Oncology Research Group from February 1997 to September 2006. The outcome of patients treated with first-line non-platinum-based chemotherapy who received platinum-based chemotherapy upon progression (cohort A) or platinum-based first-line chemotherapy followed by non-platinum-containing second-line chemotherapy (cohort B) was retrospectively analyzed. Results: Two-hundred and sixty-seven patients were identified in cohort A, and 123 in cohort B. Median follow-up time was 12.5 and 15.7 months for cohorts A and B. A significantly higher response rate and time to tumor progression (TTP) was recorded for patients treated with platinum-based compared to those receiving non-platinum-based first-line chemotherapy (45.5 vs. 21.3%, p < 0.0001 and 5.8 vs. 3.1 months, p= 0.002, respectively). Platinum-based regimens administered as second-line treatment resulted in a 13.1% response rate. TTP for second-line chemotherapy did not differ significantly between the two cohorts. Median overall survival was 13.3 and 15.7 months for cohorts A and B (p = 0.538). Conclusion: Both sequences resulted in similar efficacy in terms of overall survival. Encouraging median survival was achieved for selected patients with NSCLC who received both first- and second-line chemotherapy.

show abstract

“…So far, 2 phase II trials of docetaxel plus carboplatin as second-line treatment have been published. Wachters et al [7] administered docetaxel 75 mg/m 2 and carboplatin AUC 6 in a 21-day cycle in 57 patients who had previously received a gemcitabine-containing regimen. They observed a response rate of 37%, a median survival of 7.8 months and a 1-year survival rate of 32%.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival after Second-Line Therapy with Docetaxel and Carboplatin and Monthly Pamidronic Acid in a Woman with Metastatic Non-Small Cell Lung Cancer

Andritzky¹,

Schuch²,

Thoem³

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

Background: In patients with metastatic non-small cell lung cancer (NSCLC), second-line chemotherapy induces response rates of less than 20% and median survival times between 5 and 8 months. Case Report: In the case described here, a patient with metastastic NSCLC responded with complete remission of the primary tumor and the involved lymph nodes as well as partial remission of bone metastases to a second-line chemotherapy with docetaxel and carboplatin. Since April 2003 (33 months), no tumor progression has been observed. Until present, the patient received monthly infusions of pamidronic acid. Conclusion: Our case report indicates that in certain patients with metastatic NSCLC who did not respond to first-line regimens, second-line chemotherapy can induce outstanding tumor response and significantly improve survival. It also indicates that the role of bisphosphonates in the treatment of NSCLC should be further investigated in large clinical trials.

show abstract

Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC

Cited by 8 publications

References 27 publications

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

Non-Platinum-Based First-Line Followed by Platinum-Based Second-Line Chemotherapy or the Reverse Sequence in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis by the Lung Cancer Group of the Hellenic Oncology Research Group

Long-Term Survival after Second-Line Therapy with Docetaxel and Carboplatin and Monthly Pamidronic Acid in a Woman with Metastatic Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About